Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Gentian Diagnostics AS's Enterprise Value is kr847.1 Mil.
Gentian Diagnostics AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was kr31.1 Mil. Therefore, Gentian Diagnostics AS's EV-to-EBIT ratio for today is 27.25.
Gentian Diagnostics AS Enterprise Value Historical Data
The historical data trend for Gentian Diagnostics AS's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Gentian Diagnostics AS's Enterprise Value
For the Medical Devices subindustry, Gentian Diagnostics AS's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gentian Diagnostics AS's Enterprise Value Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Gentian Diagnostics AS's Enterprise Value falls into.
Gentian Diagnostics AS Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Gentian Diagnostics AS's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gentian Diagnostics AS (OSL:GENT) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Gentian Diagnostics AS's current Enterprise Value is kr847.1 Mil.
Gentian Diagnostics AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr31.1 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Gentian Diagnostics AS's EV-to-EBITDA for today is:
Gentian Diagnostics AS's current Enterprise Value is kr847.1 Mil.
Gentian Diagnostics AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr40.1 Mil.
Gentian Diagnostics AS's current Enterprise Value is kr847.1 Mil.
Gentian Diagnostics AS's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr158.1 Mil.
Gentian Diagnostics AS's current Enterprise Value is kr847.1 Mil.
Gentian Diagnostics AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr7.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gentian Diagnostics AS Enterprise Value Related Terms
Thank you for viewing the detailed overview of Gentian Diagnostics AS's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in-vitro diagnostic reagents (IVD) for use in medical diagnostics and research. Its portfolio and pipeline of reagents span areas of inflammations, severe infections, kidney diseases, heart failures, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP among others. Geographically, it generates a majority of its revenue from Europe followed by Asia and the United States of America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSL:GENT has been successfully added to your 